Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons dr. W.W.H. Roeloffzen

Publicaties

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma

Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse

Desensitisatie als behandeloptie bij geneesmiddelenhypersensitiviteit

Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis

Kinetics of Serum-Free Light Chain Removal by High-Cutoff Hemodialysis in Patients with Multiple Myeloma and Acute Renal Failure

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study